Champions Oncology (CSBR) to Post Quarterly Earnings on Thursday

Champions Oncology (NASDAQ:CSBR) is expected to post its Q1 2027 results after the market closes on Thursday, September 10th. Analysts expect the company to announce earnings of ($0.01) per share and revenue of $15.0450 million for the quarter. Parties may review the information on the company’s upcoming Q1 2027 earning overview page for the latest details on the call scheduled for Thursday, September 10, 2026 at 4:30 PM ET.

Champions Oncology (NASDAQ:CSBR) last issued its quarterly earnings results on Monday, July 27th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.06. The company had revenue of $13.84 million during the quarter, compared to analysts’ expectations of $12.89 million. Champions Oncology had a negative net margin of 1.87% and a negative return on equity of 27.48%.

Champions Oncology Stock Performance

Shares of CSBR opened at $4.90 on Wednesday. The stock has a market cap of $68.21 million, a PE ratio of -61.25 and a beta of 0.40. Champions Oncology has a fifty-two week low of $4.83 and a fifty-two week high of $8.74. The firm’s 50-day simple moving average is $5.46 and its two-hundred day simple moving average is $5.82.

Hedge Funds Weigh In On Champions Oncology

Several large investors have recently modified their holdings of the stock. XTX Topco Ltd bought a new position in Champions Oncology in the 2nd quarter worth about $103,000. Essex Investment Management Co. LLC purchased a new position in Champions Oncology in the fourth quarter worth about $126,000. Jane Street Group LLC purchased a new position in Champions Oncology in the first quarter worth about $200,000. Goldman Sachs Group Inc. purchased a new position in Champions Oncology in the first quarter worth about $201,000. Finally, Acadian Asset Management LLC lifted its stake in shares of Champions Oncology by 28.7% in the first quarter. Acadian Asset Management LLC now owns 39,511 shares of the biotechnology company’s stock worth $341,000 after buying an additional 8,814 shares in the last quarter. Hedge funds and other institutional investors own 41.30% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings lowered shares of Champions Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Champions Oncology presently has a consensus rating of “Sell”.

Champions Oncology Company Profile

Champions Oncology, Inc engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients.